Biospecifics Technologies Corp.

Biospecifics Technologies Corp.

Biospecifics Technologies Corp.

Overview
Date Founded

1990

Headquarters

35 Wilbur Street, Lynbrook, NY, 11563, USA

Type of Company

Public

Employees (Worldwide)

7

Industries

Pharmaceuticals
Biotechnology

Company Description

BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY.

Contact Data
Trying to get in touch with decision makers at Biospecifics Technologies Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Senior Vice President-Business Development

Principal Accounting Officer

Board of Directors

Analyst at Deutsche Bank AG (Broker)

Chief Executive Officer at Biospecifics Technologies Corp.

Associate Professor-Medicine at Yeshiva University - Albert Einstein College of Medicine

Director at Biospecifics Technologies Corp.

Vice Chairman at South Nassau Communities Hospital, Inc.

Former IBM Fellow & Chief Scientist Software Technology at International Business Machines Corporation

Paths to Biospecifics Technologies Corp.
Potential Connections via
Relationship Science
You
Biospecifics Technologies Corp.
Owners & Shareholders
Details Hidden

Rice Hall James & Associates (RHJ) currently offers five core investment strategies: Mid Cap Equity; Small Cap Equity; Micro Cap Equity; Small Cap Opportunities (formerly Small Cap Ultra Growth Equity); and Micro Cap Opportunities (formerly Micro Cap Ultra Growth Equity).For their Mid Cap Equity, Small Cap Equity and Micro Cap Equity strategies, RHJ uses a company-specific approach that focuses on identifying stocks of growth companies that are selling at a discount to those companies' projected earnings growth rates (GARP). The firm primarily invests in companies with price/earnings ratios that are lower than those companies' three- to five- year projected earnings growth rates,RHJ's Small Cap Opportunities and Micro Cap Opportunities strategies seek to take advantage of the long-term appreciation potential of smaller companies by performing disciplined fundamental research combined with the patience of longer-term holding periods. They seek to achieve above average risk-adjusted performance by selecting companies with higher estimated earnings growth rates, higher returns on invested capital, and better sustainability characteristics than that of each strategy's benchmark.

Details Hidden

Thomson Horstmann & Bryant (THB) specializes in providing investment advisory services with respect to the smaller capitalization range of the US equity market. The firm manages portfolios in a Core-with-a-Value Bias style that focuses on quality and growth. They strive to identify companies early on when they are still priced at reasonable valuations. Their investment decision process begins by employing screens of companies within the small/micro-cap universe. Several fundamental valuation techniques reduce the preliminary screen to potential companies for investment. THB looks for companies with a relatively low p/e multiple and institutional under-ownership. THB's advice is limited to the following smaller company strategies: Micro-Cap, Small-Cap Core, Small-Cap Value, Small-Cap II, and Mid-Cap.

Details Hidden

Apis Capital Advisors invests primarily in publicly traded global equity securities. The firm focuses on long and short positions of small- and mid-cap companies that have a reasonable expectation of producing above average returns. Apis takes long positions in securities they believe are undervalued, with improving business fundamentals, and short position in securities with deteriorating fundamentals that they believe are overvalued. The common characteristics for short selling may include, among other characteristics, a company that is experiencing deteriorating fundamentals, business or market catalysts impacting the company negatively, deteriorating or poor price performance, declining earnings and high valuation relative to expectations in the marketplace. In general, Apis is not constrained by diversification requirements or any other limitations as to the types of securities, other investment instruments, industries, sectors, countries or asset classes that may be invested. The firm's investment strategies may also include options, event- driven investments, private placements and the use of leverage.

Recent Transactions
Details Hidden

Healthpoint Ltd. purchases Biospecifics Technologies Corp. /Topical Collagenase Bus from Biospecifics Technologies Corp.

Advisors & Consultants
Consultant

Partner at Morgan Melhuish Abrutyn LLC

Advisor

Principal Accounting Officer at Biospecifics Technologies Corp.

Clients

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.

Key Stats and Financials As of 2019
Market Capitalization
$347M
Total Enterprise Value
$330M
Earnings Per Share
$3.33
Revenue
$38.2M
Total Equity
$124M
Net Profit
$24.5M
EBITDA
$28.4M
EBITDAMargin
74.4%
Total Debt
$236K
Enterprise Value Sales
8.63x
Enterprise Value EBITDAOperating
11.59x
TEVNet Income
13.47x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
13.31%
Five Year Compounded Annual Growth Rate Of Revenue
22.09%
Non-Profit Donations & Grants
$1,000 +
1999
Suppliers
The Research Foundation for the State University of New York Investment Services & Portfolio Management | Albany, NY

The Research Foundation of the State University of New York The RF was founded in 1951 to serve SUNY and to capitalize on its scope, scale and diversity as an engine of New York’s innovation economy. The largest, most comprehensive university-connected research foundation in the country, the RF supports nearly $1 billion in SUNY research activity annually, providing sponsored programs administration and innovation support services to SUNY faculty performing research in life sciences and medicine; engineering and nanotechnology; physical sciences and energy; social sciences, and computer and information sciences.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Biospecifics Technologies Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Biospecifics Technologies Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Biospecifics Technologies Corp..